Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has announced the extension of maturity date for its convertible promissory notes from June 30, 2025 to January 30, 2026. The extension applies to approximately $2.57 million in aggregate principal amount from the original $3.448 million bridge financing that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million (including accrued interest) into company equity.

The bridge financing participants include the company's CEO, board members, other C-suite executives, and institutional and accredited investors. The funding aims to support Jaguar's three core development programs for crofelemer: orphan disease intestinal failure program, cancer therapy-related diarrhea treatment, and expansion of Canalevia® for dogs.

Positive

• Secured extension of debt maturity providing additional 7 months of financial flexibility
• Participation from company insiders demonstrates management confidence
• $0.866 million of debt converted to equity, reducing debt burden

Negative

• Continued reliance on convertible debt financing which may lead to future dilution
• Bridge financing indicates potential cash flow challenges
• Original debt of $3.448 million still largely outstanding at $2.57 million

Insights

Financial Restructuring Specialist

Jaguar Health extends $2.57M debt maturity by 7 months, providing breathing room while signaling potential cash flow challenges.

Jaguar Health has negotiated a 7-month extension on $2.57 million in convertible promissory notes, pushing the maturity date from June 30, 2025, to January 30, 2026. This restructuring represents approximately 75% of the original $3.448 million bridge financing secured in March 2025, with the remaining $0.866 million (including accrued interest) already converted to equity by five investors prior to this extension.

The extension provides critical breathing room for Jaguar's cash flow management, suggesting the company needed additional time to meet these financial obligations. While management frames this positively as investor commitment to their development pipeline, the reality is that debt extensions typically indicate near-term liquidity constraints. The company's explicit mention of seeking "non-dilutive funding" through corporate partnerships for its three core crofelemer development programs underscores this financial pressure.

This restructuring reflects a delicate balance - avoiding immediate dilution or default while potentially postponing rather than resolving underlying cash flow challenges. The participation of insiders (CEO, board members, C-suite executives) alongside institutional investors provides some confidence, yet also indicates limited external financing options. Investors should closely monitor whether Jaguar can secure the mentioned partnerships to generate sufficient cash flow before this extended deadline arrives in early 2026.

Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing

SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.

"We're very pleased with each of the participants in this bridge financing that agreed to the extension of the maturity date," said Lisa Conte, Jaguar's Founder and CEO. "Each of these investors is committed to helping provide the resources needed to support Jaguar's goal of forging corporate partnerships to bring in non-dilutive funding for the Company's three core development programs for crofelemer, our novel plant-based prescription medicine: our orphan disease intestinal failure program; our ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and our ongoing development program to expand access for Canalevia^® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea."

To view the original terms of the bridge financing, as announced on March 26, 2025, please click here. To view the terms of the extension, please refer to the Form 8-K filed by the Company today, June 24, 2025, which can be viewed on the SEC Filings page of Jaguar's website. Click here to access the SEC Filings page of Jaguar's website.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's goal of forging corporate partnerships to bring in non-dilutive funding for the Company's three core development programs for crofelemer: the Company's orphan disease intestinal failure program; the Company's ongoing efforts to make crofelemer available for treatment of CTD in patients with metastatic breast cancer receiving selected targeted therapies; and the Company's ongoing development program to expand access for Canalevia in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the new maturity date for Jaguar Health's (JAGX) convertible notes?

The maturity date has been extended to January 30, 2026 from the previous date of June 30, 2025.

How much of Jaguar Health's bridge financing was converted to equity?

$0.866 million (including accrued interest) was converted to equity by five investors prior to the extension.

What is the current outstanding amount of JAGX's convertible notes?

Approximately $2.57 million in aggregate principal amount remains outstanding from the original $3.448 million bridge financing.

Who are the participants in Jaguar Health's bridge financing extension?

The participants include the company's CEO, board members, other C-suite executives, and institutional and accredited investors.

What will Jaguar Health use the bridge financing for?

The funding supports three core development programs for crofelemer: orphan disease intestinal failure program, cancer therapy-related diarrhea treatment, and expansion of Canalevia® for dogs.